Unpublished CTPA dose-response analysis of pulmonary artery size and mortality risk
-
Updated
Jun 20, 2026 - Stata
Unpublished CTPA dose-response analysis of pulmonary artery size and mortality risk
Analysis pipeline for the PAH biomarker study by Sonnweber T et al.
Liquidia — independent third-party profile of a public API surface, by API Evangelist. Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on the development and commercialization of inhaled therapies for cardiopulmonary disease, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with int
Lung network model of IPF and pulmonary hypertension, with a research calculator.
To associate your repository with the pulmonary-hypertension topic, visit your repo's landing page and select "manage topics."